Format

Send to

Choose Destination
Pediatr Nephrol. 2017 Feb;32(2):217-226. doi: 10.1007/s00467-016-3376-7. Epub 2016 Apr 12.

Optimizing response to desmopressin in patients with monosymptomatic nocturnal enuresis.

Author information

1
Department of Pediatrics, Aarhus University Hospital, Skejby, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. konskamp@rm.dk.
2
Department of Pediatric Nephrology, University Hospital Ghent, Ghent, Belgium.
3
Department of Pediatrics, Aarhus University Hospital, Skejby, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark.
4
University of Ghent, Ghent, Belgium.
5
Department of Pediatric Nephrology, Safepedrug Consortium, University Hospital Ghent, Ghent, Belgium.

Abstract

Most patients with monosymptomatic nocturnal enuresis can be effectively treated with an enuresis alarm or antidiuretic therapy (desmopressin), depending on the pathophysiology of the condition in the individual patient. Desmopressin is first-line therapy for enuresis caused by nocturnal polyuria, an excessive urine output during the night. However, in a recent study, around one-third of patients thought to be resistant to desmopressin were subsequently treated effectively with desmopressin monotherapy in a specialist centre. The aim of this article is to review best practice in selecting patients for desmopressin treatment, as well as outline eight recommendations for maximizing the chances of treatment success in patients receiving desmopressin. The roles of formulation, dose, timing of administration, food and fluid intake, inter-individual variation in response, body weight, adherence, withdrawal strategies and combination therapies are discussed in light of the most recent research on desmopressin and enuresis. Possible reasons for suboptimal treatment response are explored and strategies to improve outcomes in patients for whom desmopressin is an appropriate therapy are presented. Through optimization of the treatment plan in primary and specialist care centres, the hope is that fewer patients with this distressing and often embarrassing condition will experience unnecessary delays in receiving appropriate care and achieving improvements.

KEYWORDS:

Best practices; Desmopressin; Nocturnal enuresis; Treatment outcome; Treatment resistance

PMID:
27071997
PMCID:
PMC5203827
DOI:
10.1007/s00467-016-3376-7
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Compliance with ethical standards Financial disclosure KK has acted as a speaker for Ferring Pharmaceuticals. SR has acted as advisor/consultant to, and has research collaboration with, Ferring Pharmaceuticals. CVH has acted as a speaker for Ferring Pharmaceuticals. JVW has acted as advisor/consultant to, and has research collaboration with, Ferring Pharmaceuticals. Conflict of interest statement All authors declare that they have no conflicting interests involving this work.

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center